Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 4 minute read Pharma Industry News MiNK Therapeutics surges over 700% after testicular cancer remission data fuels iNKT therapy optimism MiNK Therapeutics stock explodes 730% after iNKT cell therapy shows full remission in metastatic cancer. Read what’s driving investor frenzy. byPallavi MadhirajuJuly 12, 2025